SCHEMBL5925173

SCHEMBL5925173

N[C@@H](Cc1c[nH]c2ccccc12)C(=O)OCCO

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.67
▸ KDM4E B2RXH2 3/20 0.67
▸ MEN1 O00255 2/20 0.67
▸ LMNA P02545 2/20 0.67
▸ KMT2A Q03164 2/20 0.67
▸ MPO P05164 1/20 0.67
▸ TSHR P16473 1/20 0.67
▸ BLM P54132 1/20 0.67
▸ PMP22 Q01453 1/20 0.67
▸ HIF1A Q16665 1/20 0.67
▸ TACR1 P25103 2/20 0.64
▸ HTR2A P28223 2/20 0.54
▸ ADRB1 P08588 1/20 0.54
▸ HTR1A P08908 1/20 0.54
▸ ADRA2A P08913 1/20 0.54
▸ SLC6A2 P23975 1/20 0.54
▸ HTR1D P28221 1/20 0.54
▸ HTR1B P28222 1/20 0.54
▸ HTR2C P28335 1/20 0.54
▸ HTR1E P28566 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5925171 1.00 MAPT (0.67) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL25752641 0.91 MAPT (0.62) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL29388206 0.91 MAPT (0.62) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL18274732 0.90 MAPT (0.67) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL18274731 0.90 MAPT (0.67) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL10586676 0.88 TACR1 (0.66) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL27568427 0.88 TACR1 (0.66) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL23723484 0.88 MAPT (0.76) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL29472033 0.88 MAPT (0.76) MAPTKDM4EMEN1LMNAKMT2A
Hydrochloric Acid SCHEMBL10587119 0.87 TACR1 (0.65) MAPTKDM4EMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079497-A1 Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues BALL STATE UNIVERSITY 2006-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079497-A1 Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues MCL1, LSS, MRPS18A MAPT 4317/4885KDM4E 1306/4885MEN1 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback